Nasdaq · Common stock
Faeth Therapeutics (FTH)
$16.83 −$0.25 (−1.46%)
- Day’s range
- $16.57–$18.43
- Volume
- 424,469
FTH price history
FTH closed at $16.83 on Oct. 26, 2026. Over the past year, its daily close ranged from $14.53 on June 16, 2026 to $40.05 on Sept. 4, 2026.
Data table: FTH daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $16.83 |
| Oct. 23, 2026 | $17.08 |
| Oct. 22, 2026 | $20.10 |
| Oct. 21, 2026 | $20.57 |
| Oct. 20, 2026 | $20.79 |
| Oct. 19, 2026 | $19.44 |
| Oct. 16, 2026 | $18.80 |
| Oct. 15, 2026 | $20.60 |
| Oct. 14, 2026 | $20.00 |
| Oct. 13, 2026 | $21.51 |
| Oct. 12, 2026 | $23.25 |
| Oct. 9, 2026 | $26.03 |
| Oct. 8, 2026 | $25.61 |
| Oct. 7, 2026 | $24.92 |
| Oct. 6, 2026 | $26.89 |
| Oct. 5, 2026 | $27.10 |
| Oct. 2, 2026 | $28.35 |
| Oct. 1, 2026 | $28.27 |
| Sept. 30, 2026 | $29.74 |
| Sept. 29, 2026 | $28.07 |
| Sept. 28, 2026 | $27.77 |
| Sept. 25, 2026 | $28.00 |
| Sept. 24, 2026 | $29.05 |
| Sept. 23, 2026 | $31.55 |
| Sept. 22, 2026 | $33.40 |
| Sept. 21, 2026 | $33.29 |
| Sept. 18, 2026 | $34.50 |
| Sept. 17, 2026 | $35.13 |
| Sept. 16, 2026 | $34.24 |
| Sept. 15, 2026 | $35.37 |
| Sept. 14, 2026 | $39.09 |
| Sept. 11, 2026 | $37.44 |
| Sept. 10, 2026 | $39.00 |
| Sept. 9, 2026 | $36.12 |
| Sept. 8, 2026 | $39.20 |
| Sept. 4, 2026 | $40.05 |
| Sept. 3, 2026 | $39.00 |
| Sept. 2, 2026 | $39.12 |
| Sept. 1, 2026 | $34.51 |
| Aug. 31, 2026 | $32.77 |
| Aug. 28, 2026 | $33.84 |
| Aug. 27, 2026 | $33.74 |
| Aug. 26, 2026 | $32.97 |
| Aug. 25, 2026 | $34.52 |
| Aug. 24, 2026 | $34.71 |
| Aug. 21, 2026 | $32.00 |
| Aug. 20, 2026 | $32.10 |
| Aug. 19, 2026 | $33.11 |
| Aug. 18, 2026 | $33.00 |
| Aug. 17, 2026 | $32.77 |
| Aug. 14, 2026 | $32.34 |
| Aug. 13, 2026 | $28.55 |
| Aug. 12, 2026 | $29.38 |
| Aug. 11, 2026 | $30.00 |
| Aug. 10, 2026 | $28.57 |
| Aug. 7, 2026 | $24.39 |
| Aug. 6, 2026 | $24.48 |
| Aug. 5, 2026 | $24.59 |
| Aug. 4, 2026 | $25.50 |
| Aug. 3, 2026 | $27.34 |
| July 31, 2026 | $27.24 |
| July 30, 2026 | $28.82 |
| July 29, 2026 | $28.93 |
| July 28, 2026 | $29.13 |
| July 27, 2026 | $29.24 |
| July 24, 2026 | $28.29 |
| July 23, 2026 | $27.76 |
| July 22, 2026 | $28.66 |
| July 21, 2026 | $28.37 |
| July 20, 2026 | $28.19 |
| July 17, 2026 | $25.87 |
| July 16, 2026 | $25.94 |
| July 15, 2026 | $31.47 |
| July 14, 2026 | $33.12 |
| July 13, 2026 | $33.36 |
| July 10, 2026 | $36.16 |
| July 9, 2026 | $32.54 |
| July 8, 2026 | $28.02 |
| July 7, 2026 | $26.11 |
| July 6, 2026 | $24.49 |
| July 2, 2026 | $22.92 |
| July 1, 2026 | $23.66 |
| June 30, 2026 | $25.00 |
| June 29, 2026 | $23.22 |
| June 26, 2026 | $22.87 |
| June 25, 2026 | $24.67 |
| June 24, 2026 | $24.54 |
| June 23, 2026 | $24.00 |
| June 22, 2026 | $23.19 |
| June 18, 2026 | $17.82 |
| June 17, 2026 | $16.65 |
| June 16, 2026 | $14.53 |
Key figures
- 52-week range
- —
- Average daily volume
- 362,462Past 3 months
- Market value
- $434.9M
- Dividend yield
- —
- From 52-week high
- —
Price change
- 1 month
- −39.89%
- 3 months
- −40.51%
- Year to date
- —
- 1 year
- —
What Wall Street says about FTH
In the past 90 days, Wall Street firms published 8 rating or price-target actions on FTH: 7 new ratings and 1 reiterated rating.
| Action | Rating | |||
|---|---|---|---|---|
| William Blair | Initiates coverage | Outperform | — | |
| Guggenheim | Initiates coverage | Buy | $70 | |
| LUCID CAPITAL MARKETS | Initiates coverage | Buy | $59 | |
| TD Cowen | Initiates coverage | Buy | — | |
| Needham | Initiates coverage | Buy | $56 | |
| HC Wainwright & Co. | Reiterates | Buy | $60 | |
| Jones Trading | Initiates coverage | Buy | $55 | |
| Raymond James | Initiates coverage | Outperform | $56 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Faeth Therapeutics, Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
- Headquarters
- Austin, Texas
- Employees
- 29
- Listed
- Feb. 4, 2021
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about FTH is on the site yet.